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A single-platform technology that uses an internal bead standard and three-color flow cytometry to deter-
mine CD4 and CD8 absolute counts was evaluated for reproducibility and agreement. Values obtained using
TruCount absolute-count tubes were compared to those obtained using a two-color predicate methodology.
Sixty specimens from human immunodeficiency virus type 1-infected donors were shipped to five laboratories.
Each site also analyzed replicates of 14 human immunodeficiency virus type 1-infected local specimens at 6 h
and again at 24 h. The interlaboratory variability was significantly less with TruCount (median difference in
percent coefficient of variation [%CV] between the two methods was 28% and 23% for CD4 and CD8,
respectively) than with the predicate method. Intralaboratory variability was smaller, with a median difference
in %CV of 21% for both CD4 and CD8 with 6-h samples and 22% and 23% for CD4 and CD8, respectively,
with 24-h samples. Use of TruCount for shipped samples resulted in a median CD4 count change of 7 cells
(50th estimated percentile) when all laboratories and CD4 strata were combined. For on-site samples, the
median CD4 count change was 10 CD4 cells for 6-h samples and 2 CD4 cells for 24-h samples. Individual site
biases occurred in both directions and cancelled each other when the data were combined for all laboratories.
Thus, the combined data showed a smaller change in median CD4 count than what may have occurred at an
individual site. In summary, the use of TruCount decreased both the inter- and intralaboratory variability in
determining absolute CD4 and CD8 counts.
Human immunodeficiency virus type 1 (HIV-1) infects cells
that express the CD4 receptor (8) and, as a result, depletes its
host of CD4 lymphocytes (11). This depletion of CD4 T lym-
phocytes has been linked to the immunopathogenesis of HIV
infection and progression of the disease (9, 13). A CD4 count
of #200 cells/ml has been included as an AIDS-defining event
(5), as these measurements are useful predictors for the onset
of opportunistic diseases such as Pneumocystis carinii pneumo-
nia (4). With the advent of highly active antiretroviral therapy,
CD4 T-lymphocyte measurements have been used to monitor
immune reconstitution (1).
The current predicate methodology for determining abso-
lute CD4 T-lymphocyte counts is dependent upon immuno-
phenotypic identification of cells with fluorescently labeled
monoclonal antibodies directed against the CD4 antigen. Rel-
ative percentages of CD4 T cells are determined with a flow
cytometer. An absolute CD4 count is derived by multiplying
the percentage of lymphocytes that are CD31 CD41 by the
absolute lymphocyte count determined with a hematology in-
strument. However, the overnight shipment of blood may re-
sult in increased intrinsic variability in the absolute lymphocyte
count depending on the hematology instrument that is used
(10, 16). Therefore, the absolute CD4 count in overnight sam-
ples may have increased variability due solely to the hemato-
logical determinants.
The need for precise and reproducible monitoring of CD4
T-lymphocyte levels in HIV-infected patients has led several
companies to develop simpler methods for measuring absolute
CD4 and CD8 T-lymphocyte counts (2, 7, 14, 15, 17). The new
single-platform system developed by BD Biosciences (San
Jose, Calif.) eliminates the need for multiple technologies (i.e.,
flow cytometry and hematology) and should be less expensive
than predicate methods when labor, cost and inconvenience of
repeat samples, and hematology costs are considered. Tru-
Count absolute-count tubes contain a lyophilized pellet that
dissolves during sample preparation, releasing a known num-
ber of fluorescent beads. By gating the bead population during
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analysis, absolute cell counts can be readily determined by a
simple calculation.
The purpose of this study was to evaluate the single-platform
methodology of TruCount tubes as an alternative method for
determining CD4 and CD8 absolute counts and to compare
these values with those obtained by predicate methodology.
Both reproducibility and agreement with the predicate method
were measured on centrally shipped specimens as well as on
replicate samples of specimens obtained at individual sites. In
addition, the sample stability of on-site replicate 6-h and 24-h
paired specimens was investigated.
MATERIALS AND METHODS
Evaluation sites and instrumentation. The five participating laboratories, cer-
tified by the National Institute of Allergy and Infectious Disease (NIAID) flow
cytometry proficiency program, were chosen to represent different geographical
locations from within the United States: two on the east coast, one in the
Midwest, and two on the west coast. All laboratories used a FACScan flow
cytometer equipped with either a Hewlett Packard or Macintosh Quadra com-
puter. For complete blood count and lymphocyte differential determinations,
three laboratories used Coulter STKS instruments, a fourth laboratory used a
Coulter MD 16 instrument, and the fifth laboratory used a Roche Helios instru-
ment.
Sample collection. Peripheral blood samples were obtained only from HIV-
1-infected persons. Approval and informed consent were obtained from all
participants. A central contractor, FAST Systems Inc., Gaithersburg, Md.,
shipped aliquots of EDTA-anticoagulated blood from HIV-1-infected donors to
individual sites until a total of 60 common specimens were analyzed at all sites
for flow cytometry and hematology. The mailings were received at the sites the
day following the blood drawing and were analyzed on the day of receipt. The
specimens were stratified with regard to CD4 absolute count determined by the
predicate methodology, so that approximately one-third of the shipped samples
were in each stratum: ,200, between 200 and 500, and .500 cells/ml.
In addition, each laboratory obtained EDTA-anticoagulated blood from 14
local HIV-1-infected donors in a single blood drawing consisting of two 7-ml and
sixteen 2.5-ml tubes. Eight 2.5-ml EDTA tubes were sent to the hematology
laboratory immediately for replicate determinations. One 7-ml EDTA tube was
used for eight replicate determinations of CD31 CD41 and CD31 CD81 using
the two different flow cytometric methods. The remaining EDTA tubes were
kept overnight at room temperature for 24-h measurements. Donors were pre-
screened for CD4 count to ensure that seven donors had CD4 counts of ,200
cells/ml and the other seven donors had CD4 counts of $200 cells/ml. Sites
continued to process donor specimens until 14 acceptable 6-h and 24-h paired
data sets were obtained.
Antibody staining procedure and data collection. The immunophenotyping
panels performed on all shipped and on-site specimens are listed in Fig. 1. All
reagents and computer software used for data acquisition and analysis were
supplied by BD Biosciences. For the predicate method, Simultest two-color
antibodies were used for staining and SimulSET software was used for auto-
mated data collection. The 1997 Centers for Disease Control revised guidelines
for the performance of CD4 determinations were followed for samples processed
by the two-color, stain, wash, and fix predicate method (6). For the single-
platform method, 20 ml of TriTEST three-color antibodies and 50 ml of whole
blood were added to bead-containing TruCount tubes. Tubes were incubated for
20 min at room temperature before 450 ml of FACS Lysing Solution was added.
Tubes were analyzed the same day with CELLQUEST software. The bead
population and the CD45 lymphocyte versus side scatter population were man-
ually gated. The absolute count using TruCount tubes was calculated from the
appropriate dot plot values entered into a spreadsheet that was formatted to use
the formula [(no. of events in quadrant containing cell population)/(no. of events
in absolute-count bead region [R2])] 3 [(total no. of absolute-count beads)/(test
volume [50 ml])].
Hematology measurements. The five hematology laboratories that partici-
pated in this study maintained performance that conformed to accepted stan-
dards of practice (e.g., College of American Pathologists and National Commit-
tee for Clinical Laboratory Standards). All hematology samples were drawn at
the same time as the specimens for flow cytometry. For shipped specimens, the
hematology measurements were performed within 33 h of specimen draw. For
on-site specimens, the measurements were performed within 7 h of draw for
same-day specimens and within 33 h of draw for the paired 24-h specimen data.
White blood cell (WBC) and leukocyte differential (including percent lympho-
cyte) counts were performed on an automated instrument. If the specimen was
rejected or flagged in the lymph region by the machine, the value was flagged in
the database spreadsheet and subsequently eliminated from the study analyses.
A cell designated as an atypical lymph or large unstained cell was included in the
total lymphocyte number.
Analyses. Criteria for accepting data obtained with SimulSET software in-
cluded the following: (i) gated lymphocyte purity .85%, (ii) lymphocyte recovery
within the gate .90%, and (iii) differences in the CD3 percentages between the
CD31 CD41 and CD31 CD81 tubes #7%. Data from individual sites were
entered into a spreadsheet designed by the Statistical Data Analysis Center,
Harvard School of Public Health, Boston, Mass., and imported into a central
database for analyses. Comparisons of the variability of the TruCount method
versus the predicate method were based on the Wilcoxon signed-rank test (12)
applied to the differences (TruCount method minus predicate method) in the
percent coefficient of variation (%CV) of reported CD4 and CD8 counts for each
specimen (between-laboratory %CV in the case of the centrally shipped speci-
mens and within-replicate %CV in the case of local donor specimens). The
accuracy of the CD4 and CD8 counts determined by the TruCount method
versus the predicate method was tested by the Wilcoxon signed-rank test applied
to the differences (TruCount method minus predicate method) in reported CD4
and CD8 counts for each centrally shipped specimen at each laboratory. In the
case of CD4 and CD8 counts on replicates from local donors, a log rank test
stratified by donor was used. For the primary endpoints, statistical significance is
defined as P , 0.05. The primary endpoints for both CD4 and CD8 counts, and
combining all CD4 strata, are (i) intralaboratory variability in all laboratories
combined using local specimens 24 h old, (ii) interlaboratory variability using
centrally shipped specimens, (iii) intralaboratory agreement using local speci-
mens 24 h old, and (iv) intralaboratory agreement using centrally shipped spec-
imens. The P values for the secondary endpoints are exploratory only. Tertiary
analyses on the CD4 and CD8 subset percentages were carried out similarly.
RESULTS
Interlaboratory variability for shipped specimens. CD4 and
CD8 absolute counts were obtained for 60 samples shipped to
five different laboratories. Statistical analyses of the %CVs of
the TruCount method minus the %CVs of the predicate
method were performed on the database as a whole, on the
different CD4 strata, and on individual site data. Table 1 shows
that the median %CV for the TruCount method was 8% and
3% less than the predicate method for CD4 and CD8, respec-
tively. When analyzed with regard to CD4 stratum, the ,200
cells/ml group showed a significant 23% (CD4) and 9% (CD8)
median difference in %CVs for the two methods. These large
differences were due to the large median %CVs for the pred-
icate method for samples with a CD4 count of ,200 cells/ml.
For the remaining two CD4 strata, the median differences
between methods were again significantly lower (3 to 7%),
favoring the TruCount method.
Intralaboratory variability for 6-h and 24-h replicate sam-
ples. Each of the five sites solicited 14 donors whose samples
were analyzed as eight replicates at 6 h and eight replicates at
24 h. Therefore, a total of 70 paired samples (35 with a CD4
count of ,200 cells/ml and 35 with a CD4 count of $200
cells/ml) constituted the database. Table 2 shows that the me-
dian difference in %CVs for 6-h replicate samples was 21%
(%CV for TruCount 2 %CV for predicate method) for both
CD4 and CD8 counts by both methods. When analyzed with
regard to CD4 strata, specimens with CD4 counts of ,200
cells/ml showed significant differences in the %CVs for CD4
and CD8 counts (23 and 21%, respectively). For samples with
$200 CD4 cells/ml, no differences in median %CVs between
FIG. 1. Antibody staining profiles. FITC, fluorescein isothiocyanate; PE,
phycoerythrin; PerCP, peridinin chlorophyll protein; MsIgG, mouse immuno-
globulin G.
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the two methods were seen. Individual site performance re-
flected what was observed for the database as a whole.
For the on-site replicate samples held overnight, the Tru-
Count tubes generated overall median %CV differences that
were less than the predicate method values for both CD4 and
CD8 counts (2 and 3%, respectively) (Table 3). When the
samples with a CD4 count of ,200 cells/ml were analyzed, the
median differences in %CVs were 3 and 4%, TruCount values
being less than predicate method values for CD4 and CD8
counts, respectively. Samples with a CD4 count of $200
cells/ml showed significant median differences with %CVs of
22% for CD4 counts but an insignificant 21% for CD8
counts. In general, individual site performance reflected what
was observed for the database as a whole.
Agreement for CD4 and CD8 absolute counts with the pred-
icate method for shipped samples. Agreement between meth-
ods was assessed by subtracting the absolute count obtained by
the predicate method from the absolute count obtained by the
TruCount method for the same sample, and the 10th, 50th, and
90th percentiles of the differences were estimated. For shipped
samples, with all CD4 strata and laboratories combined, the
median of the differences for CD4 and CD8 counts were 7 and
251 cells, respectively (Table 4). With all CD4 strata com-
bined, the median of the differences for CD4 counts from
individual laboratories ranged from 234 to 25 cells. Individual
site biases were noted for both CD4 and CD8 counts between
the two methods. Laboratories A and B obtained lower values
for CD4 counts using TruCount, while laboratories C, D, and
E obtained higher values with the tubes.
Agreement of CD4 and CD8 absolute counts for on-site
replicate samples. For 6-h replicate samples, the median of the
differences for CD4 and CD8 counts between TruCount and
the predicate method for all CD4 strata and laboratories were
10 and 23 cells, respectively (Table 5). The median of the
differences for CD4 and CD8 counts for the 24-h replicate
samples were 2 and 221 cells, respectively; these differences
were similar in direction and magnitude to those obtained for
the shipped samples (CD4 results similar to and CD8 Tru-
Count results lower than those with the predicate method).
Individual site biases were noted for both CD4 and CD8
counts between the two methods for both the 6-h and the 24-h
replicate samples. Laboratory B obtained lower values for CD4
counts using TruCount, while laboratories A, C, D, and E
obtained higher values with this method.
Interlaboratory variability of subset percentages. In an at-
tempt to estimate the contribution of the intrinsic variability of
the WBC and leukocyte differential counts to the combined
CD4 absolute-count variability, the subset percentages (CD31
CD41 and CD31 CD81) obtained by both methods were eval-
uated. For both shipped and 24-h on-site replicate samples, the
median %CVs obtained for CD4 and CD8 subset percentages
were significantly less using the TruCount method than the
predicate method (Table 6). The median difference in %CVs
for CD4 subset percentage was almost half for shipped samples
and about one third less for 24-h on-site replicate samples
using the TruCount tubes. For CD8 subset percentages, these
differences were of a lower magnitude: the median difference
in %CVs was about 1% lower using the TruCount tubes for
both shipped and 24-h on-site replicate samples. Similar dif-
ferences were seen when the data were analyzed with regard to
individual CD4 count stratum.
Sample stability of paired specimens analyzed at 6 and 24 h.
An indicator of sample stability was determined by subtracting
the 6-h count from the 24-h count for the same paired samples

















TruCount Predicate TruCount Predicate CD4 CD8
All 60 315 9 16 988 7 11 28* 23*
,200 21 130 11 28 620 6 22 223* 29*
200–500 24 336 8 15 989 7 8 27* 22
.500 15 714 9 10 1,256 7 10 23* 23*
a *, P , 0.05, Wilcoxon signed-rank test.
TABLE 2. Intralaboratory variability for CD4 and CD8 counts for 6-h replicate samples
CD4 stratum
or laboratory n
Median %CV absolute CD4
count





TruCount Predicate TruCount Predicate CD4 CD8
Stratum
All 70 7 7 5 5 21* 21*
,200 35 8 11 5 6 23* 21*
$200 35 6 6 5 5 0 0
Laboratory
A 14 6 7 5 5 21* 0
B 14 7 7 5 5 21 21
C 14 8 8 4 5 23 21
D 14 7 6 5 6 0 21
E 14 8 8 5 6 23 21
a *, P ,0.05, Wilcoxon signed-rank test.
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analyzed by the same method. Therefore, differences in sample
stability were determined separately for the predicate and Tru-
Count methods. For CD4 counts, the median of the difference
in fresh and day-old samples using TruCount tubes was 22
cells, compared with 4 cells using the predicate method when
all laboratories and CD4 strata were combined (Table 7). In
other words, TruCount tubes gave slightly higher CD4 values
at 6 h than at 24 h, while the predicate method gave slightly
lower values at 6 h than at 24 h. Similar differences were
observed when the CD4 strata were evaluated. Each laboratory
had its individual bias for paired samples at 6 and 24 h. Table
8 shows a similar data profile for 6-h and 24-h paired CD8
counts. When all strata and laboratories were combined, the
median of the differences in CD8 counts using TruCount was
TABLE 3. Intralaboratory variability for CD4 and CD8 counts for 24-h replicate samples
CD4 stratum
or laboratory n
Median %CV absolute CD4
count





TruCount Predicate TruCount Predicate CD4 CD8
Stratum
All 70 7 9 4 7 22* 23*
,200 35 8 10 4 8 23* 24*
$200 35 6 8 5 6 22* 21
Laboratory
A 14 5 8 4 6 23* 2*
B 14 8 10 6 6 21 0
C 14 9 9 4 8 23 25*
D 14 6 6 4 4 21 0
E 14 7 10 4 9 24* 24*
*, P , 0.05 using the Wilcoxon Signed Rank test.













10th 50th 90th 10th 50th 90th
All strata
All labs 411 272 267 7 79 ,0.01 992 2238 251 100 ,0.01
A 84 311 2103 217 61 ,0.01 1,068 2310 2136 7 ,0.01
B 74 378 2135 234 55 ,0.01 1,129 2437 2129 35 ,0.01
C 79 237 216 13 73 ,0.01 845 286 11 136
D 86 232 224 12 70 ,0.01 984 2179 244 64 ,0.01
E 88 200 225 25 181 ,0.01 927 2190 3 220
,200
All labs 168 115 249 2 40 721 2274 234 104 ,0.01
A 33 168 283 216 9 ,0.01 875 2585 2157 229 ,0.01
B 25 178 294 214 35 ,0.03 964 2491 2144 108 ,0.01
C 36 106 213 10 42 ,0.02 584 268 19 159
D 36 105 210 7 48 ,0.01 625 2114 216 61
E 38 103 224 11 55 ,0.01 680 2191 22 162
200–500
All labs 156 337 277 17 101 ,0.01 1,080 2230 265 99 ,0.01
A 33 380 2115 9 76 1,202 2247 2108 77 ,0.01
B 31 396 2169 246 62 ,0.01 1,159 2526 2129 29 ,0.01
C 27 318 228 14 83 ,0.01 1,003 286 1 114
D 33 319 221 21 83 ,0.01 1,066 2201 293 53 ,0.01
E 32 274 2239 68 225 ,0.01 1,055 2135 9 852
.500
All labs 87 680 2102 12 144 1,191 2237 263 108 ,0.01
A 18 742 2145 229 81 1,198 2202 296 73 ,0.01
B 18 752 2182 249 155 1,297 2373 2119 59 ,0.01
C 16 677 226 47 166 ,0.01 1,133 2130 3 142
D 17 622 249 12 141 1,234 2237 219 153
E 18 602 214 74 262 ,0.01 1,138 2307 27 184
a Agreement was determined by subtracting the absolute count obtained by the predicate method from the absolute count obtained by the TruCount method for the
same sample. The estimated 10th, 50th, and 90th percentiles of the differences in absolute counts (cells per microliter) are given.
b P value for the estimated 50th percentile by the Wilcoxon signed-rank test.
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higher for fresh specimens (15 cells) but lower for day-old
specimens (35 cells). Similar individual site biases were ob-
served for CD8 counts for the paired samples at both time
points. In general, the stability data showed that use of Tru-
Count tubes resulted in higher CD4 and CD8 counts at 6 h
than at 24 h.
DISCUSSION
The current method for the measurement of CD4 absolute
counts is expensive and time-consuming and requires multiple
manipulations. In addition, most laboratories require separate
tubes of blood for the flow cytometry and hematology mea-
surements. Since the hematology measurement is often sensi-
tive to small changes in the blood components, the intrinsic
variability of this measurement is especially difficult to mini-
mize. Since the interlaboratory variability in CD4 absolute
count for shipped specimens has been unacceptably large, the
values for overnight samples may not be reliable. Another
confounding factor is that different hematology instruments
may have biases toward higher or lower lymphocyte counts (3,
18). This poses a serious problem for patients on HIV-1 inter-
vention protocols if they change where their laboratory CD4
determinations are made. The high variability between any two
laboratories may make longitudinal comparisons of CD4
counts inaccurate. The availability of single-platform technol-
ogies, which determine CD4 or CD8 absolute counts using only
flow cytometry, would decrease this problem and make abso-
lute counts between institutions less variable.
In the current study, which compared single-platform Tru-
TABLE 5. Agreement between on-site replicate sample CD4 and CD8 countsa
CD4 stratum
and laboratory
CD4 count (cells/ml) CD8 count (cells/ml)
6 h 24 h 6 h 24 h
10th 50th 90th 10th 50th 90th 10th 50th 90th 10th 50th 90th
All strata
All labs 229 10b 72 262 2 65 2120 23* 194 2206 221* 140
A 222 18* 72 293 7 55 275 59* 207 2379 22 212
B 259 27* 69 2132 233* 14 2304 242* 193 2396 2140* 9
C 210 9* 66 241 2 111 252 39* 257 2169 4 234
D 225 14* 75 25 20* 89 2142 21 158 2106 11 103
E 25 21* 74 229 4 43 249 32* 183 2107 210* 110
,200
All labs 215 5* 38 235 1 38 2102 21* 202 2185 24* 154
A 214 11* 41 2156 10* 31 266 63* 227 2972 44 246
B 232 21* 58 248 225* 3 2233 233 205 2493 2142* 249
C 26 0 23 220 21 54 220 39* 208 2159 20 208
D 24 6* 36 23 12* 52 299 24 183 272 14 115
E 25 9* 43 214 6* 39 257 23 189 267 10 132
$200
All labs 250 24* 105 292 6 101 2155 25* 182 2223 238* 124
A 227 24* 87 271 2 73 277 57* 201 2288 223 172
B 284 215 112 2165 258* 42 2325 250* 156 2362 2136* 36
C 231 26* 95 264 34 149 273 38* 240 2181 226 312
D 290 36* 100 221 51* 132 2358 15 108 2158 210 89
E 27 32* 128 246 2 48 231 51* 170 2148 245* 82
a See Table 4, footnote a.
b *, P , 0.05 for the estimated 50th percentile by the Wilcoxon signed-rank test.
TABLE 6. Variability of subset percentages for shipped and 24-h on-site replicate samples
Sample group
and CD4 stratum n
Median %CV for subset Median difference in%CVsa
CD4 CD8
TruCount Predicate TruCount Predicate CD4 CD8
Shipped
All 60 5 9 2 3 24* 21*
,200 21 8 12 3 3 22* 21*
200–500 24 4 9 2 3 25* 21
.500 15 4 6 2 3 22* 0
Replicates
All 70 4 6 2 2 21* 21*
,200 35 7 9 1 2 22* 21*
$200 35 3 4 2 2 21 0*
a Calculated as TruCount %CV 2 predicate %CV. *, P , 0.05, Wilcoxon signed-rank test.
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Count tubes with a multiplatform predicate method, both the
interlaboratory and intralaboratory variability was significantly
less using TruCount tubes for both shipped and on-site repli-
cate samples. At the time that the schema was developed, the
predicate method in general use did not use CD45 gating. The
purpose of this study was to determine the differences in re-
producibility and agreement that would occur if a laboratory
switched from their current two-color predicate method to a
single-platform method. For shipped samples, the variability
between CD4 absolute counts using TruCount tubes was about




count Agreement, TruCount Pb
Median CD4
count Agreement, predicate P
24-h 6-h 10th 50th 90th 24-h 6-h 10th 50th 90th
All strata
All labs 1,120 211 219 239 22 39 ,0.01 209 200 238 4 81 ,0.01
A 224 269 279 226 6 56 ,0.01 289 254 212 25 115 ,0.01
B 224 173 183 247 28 42 ,0.01 200 210 222 20 114 ,0.01
C 224 237 224 218 1 56 190 194 245 0 65
D 224 213 217 242 23 26 ,0.01 179 191 280 212 13 ,0.01
E 224 186 192 256 29 10 ,0.01 158 177 234 0 47
,200
All labs 560 104 108 223 23 15 ,0.01 109 103 226 0 33
A 80 171 173 216 4 26 ,0.05 152 144 212 10 160 ,0.01
B 112 115 119 229 27 18 ,0.01 136 113 219 13 74 ,0.01
C 112 60 58 213 0 14 39 49 234 21 28
D 128 109 115 222 22 10 ,0.01 90 104 230 25 7 ,0.01
E 128 104 115 226 26 2 ,0.01 87 96 234 22 19
$200
All labs 560 400 387 259 21 62 401 370 257 18 103 ,0.01
A 144 320 312 235 8 66 361 305 215 37 104 ,0.01
B 112 401 401 272 211 67 498 443 225 52 142 ,0.01
C 112 418 389 231 18 91 ,0.01 402 368 266 12 98
D 96 473 492 266 28 39 406 451 2116 233 31 ,0.01
E 96 269 279 282 223 26 ,0.01 262 252 234 9 91 ,0.02
a Agreement was determined by subtracting the 6-h absolute count from the 24-h absolute count (cells per microliter) obtained for the same sample by the same
method. The estimated 10th, 50th, and 90th percentiles of the differences in absolute counts were determined.
b P value for the estimated 50th percentile, the Wilcoxon signed-rank test.




count Agreement, TruCount P
Median CD8
count Agreement, predicate P
24-h 6-h 10th 50th 90th 24-h 6-h 10th 50th 90th
All strata
All labs 1,120 795 828 2132 215 133 ,0.01 816 820 2109 35 221 ,0.01
A 224 908 945 280 65 211 ,0.01 1,051 896 210 119 401 ,0.01
B 224 970 995 2154 243 195 ,0.01 1,189 1,065 273 99 287 ,0.01
C 224 848 842 2132 210 104 ,0.01 851 827 2158 42 214 ,0.01
D 224 756 774 299 216 47 ,0.01 751 810 2149 222 68 ,0.01
E 224 675 765 2158 251 5 ,0.01 706 674 2148 0 92
,200
All labs 560 695 716 2116 219 84 ,0.01 702 684 2117 18 213 ,0.01
A 80 786 754 247 74 202 ,0.01 731 604 211 113 973 ,0.01
B 112 684 752 2138 249 106 ,0.01 1,136 985 278 122 316 ,0.01
C 112 628 634 2173 221 24 ,0.01 764 594 2183 5 199
D 128 624 640 296 211 24 ,0.01 650 694 2116 222 55 ,0.01
E 128 691 765 2107 229 13 ,0.01 668 694 2124 28 78
$200
All labs 560 926 945 2159 28 180 928 913 296 54 224 ,0.01
A 144 1,048 1,132 2139 62 216 ,0.01 1,226 1,065 210 123 320 ,0.01
B 112 1,076 1,050 2204 231 274 1,233 1,104 266 73 219 ,0.01
C 112 1,012 937 287 28 181 ,0.05 926 887 2110 68 281 ,0.01
D 96 889 894 2109 221 84 ,0.05 867 893 2249 223 80
E 96 664 754 2293 279 210 ,0.01 719 661 2166 12 108
a See Table 7, footnotes a and b.
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half that using the predicate method. One could argue that this
decrease in variability was largely due to the CD45 gating
strategy used in the TruCount method and that this decrease in
variability could also be achieved with any multiplatform
method that used three-color and CD45 gating. If this were
true, the difference in variability observed in the subset per-
centage data for the two methods should account for the ma-
jority of the decreased variability in the absolute-count data.
However, an analysis of the CD4 subset percentages showed
that only a small portion of the decreased variability could be
attributed to the use of CD45 gating. This suggests that the
TruCount method, in addition to improving the precision of
determining lymphocyte subsets over the predicate method,
also eliminated the intrinsic variability contributed by the he-
matology measurements.
When the difference in absolute counts for the same sample
by the two methods was calculated, small differences were
detected for the database as a whole. For example, the agree-
ment for the 60 shipped samples was a median CD4 count
change of 7 cells. Likewise, for on-site replicate samples, the
agreement was 10 CD4 cells for 6-h samples and 2 cells for
24-h replicate samples. However, these values were misleading
because individual sites had biases in the absolute counts that
varied in both magnitude and direction. Individual site evalu-
ations showed significant changes in absolute-count values be-
tween the two methods, but since site subset percentages did
not show these directional biases (data not shown), one must
conclude that the site’s bias in the absolute-count determina-
tions arose from the site’s hematology instrument. For exam-
ple, laboratory B used a Roche Helios hematology instrument,
and that site’s predicate-method absolute counts were consis-
tently higher than those obtained by the TruCount method
determinations compared with the other sites, which used
Coulter hematology instruments. Thus, it is important that a
site perform a comparative study to determine whether a bias
in their reported CD4 and CD8 absolute counts will occur if
they switch to a single-platform methodology.
Single-platform technology can be more cost-effective than
the predicate method when the cost of the WBC and lympho-
cyte differential counts, the time saved with reduced sample
manipulation, and the cost and inconvenience of redrawing
blood are considered. For example, the 1999 BD Biosciences
list price for the antibody reagents used in the predicate
method Simultest panel cost $32.30 per patient test. In com-
parison, the TriTEST antibody reagents cost $25.40 per patient
test. TruCount tubes add $9.60 to the cost of the TriTEST
reagents, to bring the single-platform cost to $35.00 for a
patient test. Considering that a WBC and lymphocyte differ-
ential determination costs more than $2.70 (TruCount minus
Simultest costs) and often more than $9.60 (TruCount minus
TriTEST costs), the single-platform determination is more
cost-effective than the multiplatform methods for reagents
alone. In addition, many flow cytometry laboratories are not
able to receive hematology laboratory reports by direct data
transmission. Since the hematology results must be received by
the flow cytometry laboratory before CD4 and CD8 absolute
counts can be calculated, misplaced reports can result in ab-
solute-count reporting delays. Occasionally, the tube of blood
for the hematology laboratory is not drawn and the CD4 and
CD8 absolute counts cannot be reported for the patient sam-
ple. In other circumstances, sample quality is so poor that the
hematology instrument cannot perform a reliable lymphocyte
differential, and again absolute counts cannot be calculated.
When hematology values are unattainable for these various
reasons, bead-based, single-platform technology can provide
meaningful absolute-count data.
Some single-platform methods do not directly determine
lymphocyte percentages and only give CD4 and CD8 absolute
counts. Examples include the FACSCount system, the Ortho
Cytoron Absolute system, the Zymmune CD4/CD8 cell mon-
itoring kit from Zynaxis, Inc. (7), volumetric capillary cytom-
etry from Biometric Imagining, Inc. (15), and the TRAx CD4
test kit from T Cell Diagnostics, Inc. (17). However, TruCount
tubes and Flow-Count fluorospheres (Beckman Coulter) pro-
vide lymphocyte subset percentages as well as absolute counts.
The determination of both of these clinical parameters is im-
portant because the lymphocyte subset values are often re-
quired for monitoring pediatric HIV-positive populations.
In the present study, the predicate method used forward
light scatter versus side scatter in comparison to the TruCount
method, which used CD45 lymphocyte gating for sample ac-
quisition and analysis. CD45 lymphocyte gating is also rou-
tinely used today by flow cytometric laboratories performing
three-color, multiplatform analyses and is not unique to the
bead-based, single-platform technology used in this study. De-
generative samples that must be analyzed with a gating strategy
based on forward light scatter versus side scatter often fail to
meet acceptable gating criteria and result in blood specimens
having to be retested or redrawn. For example, in order for the
60 shipped samples to be analyzable at all five sites, a total of
90 specimens were actually sent to the laboratories. The ma-
jority of extra specimens were needed because of unacceptable
gating criteria for the shipped samples by the predicate
method. However, for those samples that could not be ana-
lyzed with the predicate method, CD4 and CD8 absolute
counts were almost always obtained by using CD45 lymphocyte
gating. The TruCount method had an additional advantage
over a three-color multiplatform method in that it could “res-
cue” samples for which an absolute count could not be calcu-
lated because of invalid or incomplete hematology values.
In summary, the TruCount method gave better reproduc-
ibility and agreement for both shipped and on-site replicate
samples than a multiplatform predicate method. In addition to
being more cost-efficient, valid absolute cell counts for degen-
erative samples could be consistently obtained by the single-
platform method. Therefore, the results of this multisite study
support the use of bead-based, single-platform technology for
routine clinical assessment of CD4 and CD8 absolute cell
counts.
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